Cover Image
市場調查報告書

豬流感的開發中產品分析

Swine Influenza - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 192616
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
豬流感的開發中產品分析 Swine Influenza - Pipeline Review, H2 2014
出版日期: 2014年11月14日 內容資訊: 英文 31 Pages
簡介

豬流感病毒是全球各地豬的共通病毒。由豬感染人類並不常見,還有人類並不只是流感發病,通常結果會在血液內產生抗體。如果從豬感染人類而發病了,稱為「人畜共通型(zoonotic)豬流感」。日常有機會接觸豬隻的人們,感染這種豬流感的風險較高。

本報告提供全球各國的豬流感治療方法的開發中產品的開發情形相關分析、開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,再加上主要企業簡介、主要藥物概要(產品概要、功能機制、研究開發(R&D)的發展情形)、最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

豬流感概要

治療藥的開發

  • 豬流感的開發中產品:概要
  • 豬流感的開發中產品:比較分析

各企業開發中的豬流感治療方法

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確階段的產品

各企業開發中的產品

參與豬流感治療藥開發的企業

  • Novartis AG
  • OPKO Health, Inc.
  • Aprogen, Inc.
  • Pike Pharma GmbH
  • Greffex, Inc.
  • Lakewood-Amedex Inc.

豬流感治療方法的評估

  • 單劑治療藥的情況
  • 各標的
  • 各行動機制
  • 各投藥法
  • 分子的各類型
  • 各藥效分類(Therapeutic Class)

藥物簡介

  • H3N2c疫苗
  • 流感疫苗
  • Influ-nRNA
  • GREFLU/CAL
  • Fluinhibit
  • AP-302

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5759IDB

Summary

Global Markets Direct's, 'Swine Influenza - Pipeline Review, H2 2014', provides an overview of the Swine Influenza's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Swine Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Swine Influenza and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Swine Influenza
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Swine Influenza and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Swine Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Swine Influenza pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Swine Influenza
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Swine Influenza pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Swine Influenza Overview
  • Therapeutics Development
    • Pipeline Products for Swine Influenza - Overview
    • Pipeline Products for Swine Influenza - Comparative Analysis
  • Swine Influenza - Therapeutics under Development by Companies
  • Swine Influenza - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Swine Influenza - Products under Development by Companies
  • Swine Influenza - Companies Involved in Therapeutics Development
    • Aprogen, Inc.
    • Novartis AG
    • OPKO Health, Inc.
  • Swine Influenza - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AP-302 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Flu Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GREFLU/CAL - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Influ-nRNA - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [H3N2] (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Swine Influenza - Recent Pipeline Updates
  • Swine Influenza - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Swine Influenza, H2 2014
  • Number of Products under Development for Swine Influenza - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Swine Influenza - Pipeline by Aprogen, Inc., H2 2014
  • Swine Influenza - Pipeline by Novartis AG, H2 2014
  • Swine Influenza - Pipeline by OPKO Health, Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Swine Influenza Therapeutics - Recent Pipeline Updates, H2 2014
  • Swine Influenza - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Swine Influenza, H2 2014
  • Number of Products under Development for Swine Influenza - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top